Aspirin and Vascepa are two different medications with different mechanisms of action, but they are both used to reduce the risk of cardiovascular events in certain adult patient groups. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the production of prostaglandins, which are involved in inflammation, pain, and fever [1]. Vascepa, on the other hand, is a prescription omega-3 fatty acid medication that works by reducing triglyceride levels in the blood [2].

There is no direct evidence to suggest that aspirin impacts Vascepa's effectiveness. However, the prescribing information for Vascepa states that caution should be exercised when using it with other drugs that affect bleeding, such as aspirin, because of the potential for increased bleeding [3]. Therefore, patients taking both Vascepa and aspirin should be closely monitored for signs of bleeding, and the dose of aspirin may need to be adjusted to minimize the risk of bleeding [3].

In summary, while there is no direct evidence to suggest that aspirin impacts Vascepa's effectiveness, caution should be exercised when using the two drugs together due to the potential for increased bleeding. Patients taking both medications should be closely monitored for signs of bleeding, and the dose of aspirin may need to be adjusted to minimize the risk of bleeding.

Sources:
[1] DrugPatentWatch. Aspirin. Retrieved from https://www.drugpatentwatch.com/p/tradename/ASPIRIN
[2] FDA. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
[3] FDA. Vascepa (icosapent ethyl) capsules, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf.